ERBB2 and breast cancer: The ALKBH5-mediated N6-methyladenosine demethylation of GLUT4 mRNA promotes resistance to HER2-targeted treatment, suggesting that targeting the ALKBH5/GLUT4 axis has therapeutic potential for treating patients with refractory BC.142